Skip to content
AnecdotalSenolytic peptide for cellular rejuvenation

FOXO4-DRI

Senolytic peptide that clears aged & damaged cells.

Overview

Binds to FOXO4 protein, displacing p53 and activating pro-apoptotic pathways only in senescent cells.

Proposed mechanism

FOXO4-DRI is a D-retro inverso peptide that disrupts FOXO4-p53 interaction, triggering apoptosis selectively in senescent cells.

What the evidence supports

Evidence rests primarily on self-reported experience. Controlled studies are lacking.

Graded Anecdotal

Case reports, clinician notes, and user-reported outcomes. Recorded for completeness and labelled plainly so it is never mistaken for data.

Key citations

Representative primary sources, including results that did not favour the compound.

  1. [1]

    FOXO4-DRI in aged mice

    · DOI:10.1016/j.cell.2017.03.048 · 2017

  2. [2]

    Senolytics review

    · DOI:10.1038/s41591-018-0225-0 · 2018

  3. [3]

    FOXO4-DRI in aged mice (2017)

    · · 0

  4. [4]

    Senolytics review (2018)

    · · 0

Citation records in this build are illustrative placeholders for the design.

Reference information for research purposes. Not medical advice, and not a recommendation to use any compound. Many entries describe substances that are not approved for human use.

Related profiles

Acetyl Tetrapeptide-3 (Darnosine)

Animal

Acetyl tetrapeptide-3 for AGE prevention

Advanced AGE-breaker for deep anti-wrinkle action.

0 RCT · 0 human · 0 preclinical

longevity

AHK-Cu

Human-limited

Copper peptide for skin regeneration and repair

AHK-Cu is a copper-binding tripeptide (Ala-His-Lys) complexed with copper(II) ions, closely related to the well-studied GHK-Cu peptide. It stimulates collagen and glycosaminoglycan synthesis in skin fibroblasts while exerting antioxidant and anti-inflammatory activity. Primarily researched in the context of skin regeneration, wound healing, and hair follicle stimulation.

0 RCT · 0 human · 0 preclinical

skin

Cardiogen

Human-limited

Cardiac peptide bioregulator for heart longevity

Cardiogen is a short synthetic tetrapeptide (Ala-Glu-Asp-Arg) originally developed by the St. Petersburg Institute of Bioregulation and Gerontology in Russia, designed to support cardiac tissue health and function. It acts as a cytoprotective bioregulator targeting cardiomyocytes, promoting cellular repair and reducing age-related deterioration in heart muscle tissue. Research, primarily from Russian preclinical and limited clinical studies, suggests it may help maintain cardiac contractility, reduce fibrosis, and support overall cardiovascular resilience.

0 RCT · 0 human · 0 preclinical

Cardiovascular